2-Amino-3-oxo-3-[4-(tetradecyloxy)anilino]propyl dihydrogen phosphate | 556810-88-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Amino-3-oxo-3-[4-(tetradecyloxy)anilino]propyl dihydrogen phosphate
• 英文别名: [2-Amino-3-oxo-3-(4-tetradecoxyanilino)propyl] dihydrogen phosphate
• CAS: 556810-88-9
• 化学式: C₂₃H₄₁N₂O₆P
• 分子量: 472.562
• InChiKey: JPOQRZYACXOTHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  32
• 可旋转键数：
  19
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  131
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• LPA receptor agonists and antagonists and methods of use
  申请人：——

  公开号：US20030027800A1

  公开（公告）日：2003-02-06

  The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, and treating a wound.

  本发明涉及根据此处披露的公式（I）的化合物，以及包括这些化合物的药物组合物。还披露了使用这些化合物的方法，这些化合物具有作为LPA受体激动剂或拮抗剂的活性；这些方法包括抑制LPA对LPA受体的活性，调节LPA受体活性，治疗癌症，增强细胞增殖，并治疗伤口。
• LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE
  申请人：THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION

  公开号：EP1263752B1

  公开（公告）日：2007-12-05
• EP1427424A4
  申请人：——

  公开号：EP1427424A4

  公开（公告）日：2006-12-13
• US6875757B2
  申请人：——

  公开号：US6875757B2

  公开（公告）日：2005-04-05
• [EN] LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE<br/>[FR] AGONISTES ET ANTAGONISTES DU RECEPTEUR DE L'ACIDE LYSOPHOSPHATIDIQUE ET PROCEDES D'UTILISATION
  申请人：UNIV TENNESSEE RES CORP

  公开号：WO2003024402A2

  公开（公告）日：2003-03-27

  The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.